Delving into the Latest Updates on Beijing Health Guard Biotechnology, Inc. with Synapse

Overview

Tags

Infectious Diseases

Digestive System Disorders

Urogenital Diseases

Prophylactic vaccine

Vaccine

Genetically engineered subunit vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	12
Neoplasms	2
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Prophylactic vaccine	7
Vaccine	4
Genetically engineered subunit vaccine	2
Therapeutic vaccine	1
Monoclonal antibody	1

Top 5 Target	Count

SARS-CoV-2 antigen	1

Human papillomavirus (HPV) is the infectious etiol. agent for diseases such as cervical cancer.Developing HPV vaccines is of great significance for cancer prevention.During the development of polyvalent HPV vaccines, such as 9-valent and 15-valent HPV vaccines, specifical identification of different HPV antigen is very important.The homemade HPV31 L1 VLPs was used as an immunogen to generate HPV 31 monoclonal antibodies (mAbs) through hybridoma cell culture.We generated several mAbs through hybridoma cell culture and selected two specific neutralizing antibodies, 19B2 and 19C4, which were further analyzed and characterized for binding activity, neutralizing activity, and specificity by enzyme-linked immunosorbent assays (ELISA).It is shown that both 19B2 and 19C4 could specifically recognize HPV31 L1 virus-like particles (VLPs).These two specific mAbs were further used to assemble a HPV31 antigen ELISA test kit.The assembled kit with high detection performance could be widely applied for the quant. detection of HPV31 antigen during vaccine production as well as in the preliminary anal. of HPV31 infection.

14 Aug 2023·Vaccine

Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.

Article

Author: Gao, Wenshuang ; Li, Ling ; Zhang, Yao ; Jiang, Xulin ; Zhang, Hongcai ; Yin, Fei ; Shen, Ercui ; Li, Yakun ; Liu, Yongjiang ; Shi, Yazheng ; Liu, Yuying ; Chen, Xiao ; Du, Xiaoli ; Wen, Hongyan ; Zhang, Aijing ; Yang, Xiufen ; Wang, Yan ; Yang, Zengmin ; Zhang, Haijiang ; Zhu, Jiaton ; Yang, Jianguo ; Fu, Sijia ; Guo, Qian ; Wu, Shuming ; Chen, Dan ; Guo, Jiaping

Coronavirus disease (COVID-19) is still spreading rapidly worldwide, and a safe, effective, and cheap vaccine is still required to combat the COVID-19 pandemic. Here, we report a recombinant bivalent COVID-19 vaccine containing the RBD proteins of the prototype strain and beta variant. Immunization studies in mice demonstrated that this bivalent vaccine had far greater immunogenicity than the ZF2001, a marketed monovalent recombinant protein COVID-19 vaccine, and exhibited good immunization effects against the original COVID-19 strain and various variants. Rhesus macaque challenge experiments showed that this bivalent vaccine drastically decreased the lung viral load and reduced lung lesions in SARS-CoV-2 (the causative virus of COVID-19)-infected rhesus macaques. In summary, this bivalent vaccine showed immunogenicity and protective efficacy that was far superior to the monovalent recombinant protein vaccine against the prototype strain and provided an important basis for developing broad-spectrum COVID-19 vaccines.

01 Feb 2023·Preparative Biochemistry & BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Development of HPV58 type-specific antibodies and detection kit

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Zhang, Guifeng ; Liu, Yuying ; Zhang, Yao ; Yang, Zengmin ; Wang, Yan ; Wu, Shuming ; Chen, Dan ; Zhang, Haijiang ; Liu, Yongjiang

Currently, human papillomavirus (HPV) vaccines are in short supply, so the development of HPV vaccines has a broad market prospect. The 3-, 9-, and 15-valent HPV vaccines developed by ourselves all contain HPV58-derived antigen components. It is important to detect HPV 58 during vaccine production. Here, we introduced a development process of HPV58 type-specific antibodies and a detection kit. Briefly, HPV58 L1-Virus Like Particles (VLPs) were used as antigens to immunize mice, followed by extraction of the ascites to prepare hybridoma cells. After culturing, the supernatants containing secreted antibodies were harvested, purified, and screened to obtain monoclonal antibodies (mAbs). In the pool of attained monoclonal antibodies, we selected 2F7 and 2G7 to evaluate their subtypes, specificity, neutralizing activity, serum competition, binding affinity and gene sequencing. Finally, an enzyme-linked immunosorbent assay (ELISA) detection kit was assembled with 2F7 and 2G7 mAbs which possessed high specificity to HPV58 L1-VLPs. The detection kit developed by 2F7 and 2G7 could be adopted to specifically detect HPV58 L1 protein with good linearity and detection range, which could be widely used in clinical testing and quality control in the production of HPV vaccines.Abbreviations: BSA: Bovine serum albumin; CDRs: Complementarity-determining regions; CV: Coefficient of variation; DTT: Dithiothreitol; ELISA: Enzyme-linked immunosorbent assay; HAT: Hypoxanthine-aminopterin-thymidine; HPV: Human Papillomavirus; IC₅₀: 50% inhibition rate; IC₉₀: 90% inhibition rate; mAbs: Monoclonal antibodies; VLP: Virus-like particle.

100 Deals associated with Beijing Health Guard Biotechnology, Inc.

Login to view more data

100 Translational Medicine associated with Beijing Health Guard Biotechnology, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

7

Preclinical

IND Application

1

Phase 1 Clinical

Phase 3 Clinical

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant nine-valent human papillomavirus(6/11/16/18/31/33/45/52/58)vaccine(Beijing Health Guard Biotechnology)	Anal intraepithelial neoplasia More	Phase 3
Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)	Vulvar Neoplasms More	Phase 3
Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)	Human Papillomavirus Infection More	Phase 1
Recombinant 2-valent COVID-19 vaccine(Beijing Health Guard Biotechnology)	COVID-19 More	IND Application
Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)	Gastroenteritis More	Preclinical